ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cardiac - Pharmacology

November 9, 2021
A good-size Terumo-sponsored RCT that is set to impact on decisions to discontinue DAPT early after PCI with absorbable stent, a change that will somehow decrease the surgical risk of bleeding in the event of salvage CABG. 
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
February 21, 2021
An editorial that may herald the decrease in aspirinization and the rise of ticagrelor monotherapy in Percutaneous stenting of coronary arteries.
November 28, 2020
A large RCT with results somewhat supportive of considering a NOAC in the place of warfarin for post operative surgical patients. The study will be weighed against healthcare economical aspects.
November 17, 2020
A latge RCT of the first myosin inhibitor in severe chronic heart failure: somewhat difficult to interpret results, as deaths were slightly higher in the intervention group while there was no 'significant' benefit in cardiovascular deaths.
August 18, 2020
A review that may affect pharma strategy in the immediate future.
May 11, 2020
Interesting hypothesis in a rodent model of myxomatous degeneration.
February 20, 2020
The authors revisit the older, somewhat misinterpreted hypothesis of cocoa and vasodilation. The title may again be misinterpreted by the general media as an encouragement to gorge on HIGH CALORIE, HIGH FAT nutrients
November 22, 2019
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
November 18, 2019
An editorial related to a recent randomized controlled trial suggesting a striking benefit of anti-inflammatory secondary prevention after recent myocardial events.

Pages